Drugs / MGD010
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03955666 | Aug → Dec 2019 | — | Provention Bio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02376036 | Feb 2015 → Feb 2017 | — | MacroGenics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05087628 | Jan 2022 → May 2024 | systemic lupus erythematosus | Provention Bio, a Sanofi Company | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-09-12 | Takeda | Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement takeda.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MGD010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02376036 ↗ |
| Known as | PRV-3279 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05087628 ↗ |
| Route | Intravenous | “Subjects will receive MGD010 through IV infusion.” NCT02376036 ↗ |
| Target | CD79B | “MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct” NCT02376036 ↗ |